CDTX Cidara Therapeutics, Inc.

-0.10  -1%
Previous Close 6.75
Open 6.70
Price To book 1.49
Market Cap 111.76M
Shares 16,806,000
Volume 81,100
Short Ratio 3.30
Av. Daily Volume 103,315

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiated June 2016. Data due 4Q 2017.
Phase 2 data released February 21, 2017 - efficacy not evident, Development to be discontinued.
CD101 Topical - RADIANT
Vulvovaginal candidiasis (VVC)

Latest News

  1. Cidara Therapeutics reports 1Q loss
  2. Cidara Provides Corporate Update and Reports First Quarter 2017 Financial Results
  3. Is a Surprise Coming for Cidara Therapeutics (CDTX) This Earnings Season?
  4. Cidara Therapeutics Announces Promotion of Taylor Sandison, M.D., M.P.H., to Chief Medical Officer
  5. Cidara Therapeutics to Present Data on Novel Antifungal CD101 and Cloudbreak Antibacterial Immunotherapy at ECCMID and SID Annual Meetings
  6. The Zacks Analyst Blog Highlights: Esperion Therapeutics, Vertex Pharmaceuticals, Nektar Therapeutics, Argos Therapeutics and Cidara Therapeutics
  7. 3 of the Best & Worst Performing Drug Stocks of Q1
  8. Cidara Therapeutics Awarded $6.9 Million Grant from CARB-X to Advance Development of its First CloudbreakTM Antibiotic Immunotherapy
  9. Cidara Therapeutics to Host Investor Day on April 6, 2017
  10. Arbutus Announces Appointment of Daniel Burgess to Board of Directors
  11. Cidara Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results
  12. Is The Cidara Therapeutics Inc (CDTX) Crash An Opportunity?
  13. Cidara Yeast Infection Gelm Fails Phase 2 Trial
  14. Antimicrobials Working Group Announces New Leadership Team
  15. Cidara Therapeutics Completes Enrollment in Phase 2 RADIANT Trial Evaluating Novel Antifungal CD101 Topical in Vulvovaginal Candidiasis
  16. Newly Published Data Reinforce Growing Body of Evidence Supporting Cidara Therapeutics’ Lead Antifungal CD101
  17. Hedge Funds Aren’t Crazy About Cidara Therapeutics Inc (CDTX) Anymore
  18. Cidara Therapeutics, Inc. :CDTX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 29, 2016